• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    89Bio Inc (NQ: ETNB )

    7.780 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about 89Bio Inc

    < Previous 1 2 3 4 5 6 7 8 Next >
    89bio to Participate in the Leerink Partners Global Biopharma Conference
    From 89bio, Inc.
    Via GlobeNewswire
    Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported preliminary fourth-quarter financial results, announced the successful testing of its... 
    Via Benzinga
    Analyst Ratings for 89bio
    Via Benzinga
    Analyst Expectations for 89bio's Future
    Via Benzinga
    Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
    Akero and 89bio stocks are poised to top their 200-day moving averages on the results of Akero's MASH treatment in midstage testing. 
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    We're starting off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday morning! 
    Via InvestorPlace
    89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
    From 89bio, Inc.
    Via GlobeNewswire
    Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
    The results from Boehringer Ingelheim and Zealand Pharma bolstered some biotech stocks. But not all got the same boost. 
    Via Investor's Business Daily
    89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
    89Bio's journey in the clinical-stage biopharmaceutical space. RBC Capital Markets downgrades with insights on FGF21 drugs, pegozafermin, and 2024 uncertainties. 
    Via Benzinga
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From 89bio, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
    From 89bio, Inc.
    Via GlobeNewswire
    Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CXM) shares fell sharply in pre-market trading following... 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
    89bio Inc (NASDAQ: ETNB) announced a successful end-of-Phase 2 Meeting with the FDA supporting the advancement of pegozafermin into Phase 3 in  
    Via Benzinga
    Exposures Product Safety
    89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
    From 89bio, Inc.
    Via GlobeNewswire
    89bio's Fatty Liver Candidate Shows Long-Term Improvement: Details
    89bio Inc (NASDAQ: ETNB) released topline data from the blinded extension phase of its Phase 2b ENLIVEN trial evaluating treatment with pegozafermin in patients with  
    Via Benzinga
    89bio Announces New Positive Long-Term Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis (NASH)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Participate in the 6th Annual Evercore ISI HEALTHCONx Conference
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
    From 89bio, Inc.
    Via GlobeNewswire
    89bio to Participate in the H.C. Wainwright 7ᵗʰ Annual NASH Investor Conference
    From 89bio, Inc.
    Via GlobeNewswire
    Why Shares of 89bio Plummeted on Tuesday
    So-so trial data for a competitor's NASH therapy candidate that is similar to 89bio's candidate spooked investors. 
    Via The Motley Fool
    Akero Therapeutics' Disappointing NASH Data Drags Its Rival
    Earlier today, Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to  
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.